Dimensional Fund Advisors LP Boosts Holdings in Charles River Laboratories International, Inc. $CRL

Key Points

• Dimensional Fund Advisors LP increased its stake in Charles River Laboratories by 30%, acquiring an additional 198,750 shares, bringing their total ownership to approximately 862,254 shares valued at $129.8 million.
• Charles River Laboratories reported $3.12 EPS in its latest earnings, surpassing analysts' expectations of $2.50, while its revenue rose by 0.6% over the previous year.
• Recent ratings from analysts include upgrades from Citigroup and Evercore ISI, with a consensus rating of "Hold" and an average price target of $175.69 for the stock.

Dimensional Fund Advisors LP increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 30.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 862,254 shares of the medical research company's stock after acquiring an additional 198,750 shares during the period. Dimensional Fund Advisors LP owned about 1.76% of Charles River Laboratories International worth $129,799,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. D1 Capital Partners L.P. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $172,752,000. Assenagon Asset Management S.A. increased its holdings in Charles River Laboratories International by 1,721.1% in the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after buying an additional 538,792 shares during the last quarter. Nomura Holdings Inc. bought a new position in Charles River Laboratories International in the 4th quarter worth approximately $56,820,000. SG Americas Securities LLC lifted its position in shares of Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company's stock valued at $40,219,000 after acquiring an additional 265,558 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Charles River Laboratories International by 24,226.8% in the first quarter. GAMMA Investing LLC now owns 210,427 shares of the medical research company's stock valued at $31,673,000 after purchasing an additional 209,562 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company's stock, valued at $3,800,681.60. This represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on CRL. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price target for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Wall Street Zen cut shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 17th. Evercore ISI boosted their price target on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. Finally, Robert W. Baird upped their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Five research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $175.69.

Charles River Laboratories International Stock Down 0.7%

Shares of Charles River Laboratories International stock traded down $1.11 during trading hours on Tuesday, reaching $163.00. The company's stock had a trading volume of 183,740 shares, compared to its average volume of 1,256,745. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The stock's fifty day simple moving average is $157.92 and its two-hundred day simple moving average is $148.53. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02. The company has a market capitalization of $8.02 billion, a P/E ratio of -122.67, a P/E/G ratio of 5.16 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same quarter last year, the company earned $2.80 earnings per share. The company's revenue was up .6% on a year-over-year basis. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).